Results 151 to 160 of about 728 (161)

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure
Roberto Barriales Villa, Perry M Elliott, Artur Oreziak   +2 more
exaly  

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Stephen B Heitner, Stuart Kupfer, Fady I Malik   +2 more
exaly  

SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM

Medicom Conference Report HFA 2024
openaire   +1 more source

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure
Perry M Elliott, Ajith P Nair, Stephen B Heitner   +2 more
exaly  

EFFECT OF AFICAMTEN TREATMENT FOR UP TO 72 WEEKS ON CARDIAC STRUCTURE AND FUNCTION IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: THE SEQUOIAHCM AND FOREST-HCM CMR SUB-STUDIES

Journal of the American College of Cardiology
A. Masri, Rhanderson Cardoso, M. Nassif, Béla Merkely, A. Oręziak, T. Abraham, R. B. Villa, L. Choudhury, C. Coats, P. Elliott, A. T. Owens, F. Rader, S. Saberi, S. Solomon, A. Tower-Rader, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, C. Melloni, Jenny Wei, A. Wohltman, Christopher M. Kramer, Raymond Y. Kwong, Martin S. Maron   +24 more
semanticscholar   +1 more source

Aficamten and Cardiopulmonary Exercise Test Performance

JAMA Cardiology
Roberto Barriales Villa, Stephen B Heitner, Stuart Kupfer   +2 more
exaly  

Aficamten Monotherapy for Hypertrophic Cardiomyopathy

New England Journal of Medicine
exaly  

SEQUOIA-HCM: Aficamten safe and efficacious for HCM across the globe

Medicom Conference Report HFA 2025
openaire   +1 more source

Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?

Journal of the American College of Cardiology
Enrico, Ammirati, Guglielmo, Gallone
openaire   +1 more source

Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA.

Journal of the American College of Cardiology
openaire   +1 more source